Pfizer Sticking To “Plan A,” But Read Says That Doesn’t Require AstraZeneca
This article was originally published in The Pink Sheet Daily
Executive Summary
If Pfizer’s ambition to grow through a combination with AstraZeneca doesn’t come to pass, there is no Plan B, CEO Ian Read says during the big pharma’s second quarter earnings call.
You may also be interested in...
Pfizer’s Latest Palbociclib Data Could Mean Slimmer Lead Over CDK4/6 Rivals
Final Phase II data for palbociclib in breast cancer at AACR meeting raise questions about prospects for accelerated approval prior to Phase III results. Meanwhile, Lilly’s bemaciclib emerges as potent monotherapy with seemingly lower risk for neutropenia, but more data are needed to flesh out the drug’s profile.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.